We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Regional Specificity of Layer 3 Dendritic Spine Deficits in Schizophrenia: Implications for Cortical Circuit Dysfunction

MedXY Editorial Team•Oct 27, 2025•Neurology
schizophrenia

Highlight

  • Schizophrenia (SZ) is associated with distinct reductions in layer 3 dendritic spine density across primary visual, posterior parietal, and dorsolateral prefrontal cortices.
  • Spine size-dependent deficits were regionally specific, affecting small spines in V1 and medium to large spines in PPC and DLPFC.
  • Altered fluorescence intensities of F-actin and spinophilin suggest region-dependent changes in synaptic stability and plasticity in SZ.
  • Findings suggest that different cortical nodes contributing to visual-spatial working memory are differentially impacted at the synaptic level in SZ.

Study Background

Schizophrenia is a chronic and severe neuropsychiatric disorder characterized by disturbances in cognition, perception, and behavior. Among the cognitive impairments, deficits in visual-spatial working memory are prominent and closely linked to the disease’s functional disability. Visual-spatial working memory depends on the integrity of a distributed cortical network involving the primary visual cortex (V1), posterior parietal cortex (PPC), and dorsolateral prefrontal cortex (DLPFC). The connectivity across these nodes is mediated primarily by excitatory synapses on dendritic spines of pyramidal neurons in layer 3 (L3) of the neocortex.

Abnormalities in dendritic spine density and morphology have long been hypothesized to underlie synaptic pathology in SZ. Dendritic spines are small membranous protrusions that receive excitatory inputs; their density and structure are indicative of synaptic health, plasticity, and stability. Previous studies indicated spine deficits in prefrontal regions in SZ but lacked a comprehensive assessment across multiple cortical areas critical for visual-spatial working memory and differentiation by spine size.

Study Design

This study is a case-control neuropathological investigation involving postmortem brain tissue obtained from 20 individuals with a confirmed diagnosis of schizophrenia and 20 matched unaffected comparison (UC) individuals. Subjects were matched for age, sex (70% male, 30% female in both groups), and other relevant demographic characteristics to minimize confounding.

Brain regions analyzed included the primary visual cortex (V1), posterior parietal cortex (PPC), and dorsolateral prefrontal cortex (DLPFC). Layer 3 pyramidal neurons were isolated for dendritic spine analysis. Spines were fluorescently labeled using phalloidin to stain F-actin, which marks the spine cytoskeleton, and immunolabeling for spinophilin, a protein associated with dendritic spine stability and synaptic function. Confocal microscopy enabled high-resolution imaging and quantitative analyses of spine density, size classes (small, medium, large), and fluorescence intensity.

Key Findings

The primary outcome measures were comparisons of dendritic spine density and size distributions between SZ and UC groups across the specified cortical regions.

1. Dendritic Spine Density Deficits Are Region- and Size-Specific:
– In V1, individuals with SZ had a significant reduction of 18% in the density of small spines (95% CI: -31% to -5%; P = .009).
– In PPC, medium spines were reduced by 16% (95% CI: -28% to -4%; P = .01), and large spines showed a substantial 38% reduction (95% CI: -58% to -17%; P < .001).
– In DLPFC, medium and large spines were also reduced (medium spines: -13%, 95% CI: -21% to -4%; P = .009; large spines: -30%, 95% CI: -50% to -11%; P = .004).

2. Alterations in Spine Structural Markers:
– Phalloidin fluorescence, indicating F-actin content, was decreased in small (-9.5%, P = .04) and medium (-9.8%, P = .04) spines in V1 but paradoxically increased by 9.5% (P = .049) in large spines of DLPFC, suggesting region- and size-specific cytoskeletal remodeling.
– Spinophilin fluorescence intensity was consistently lower across all spine sizes and regions in SZ, ranging from a 13% to 34% decrease (P values .02 to <.001), underscoring a general deficit in synaptic scaffolding proteins.

3. Link to Functional Impairment:
Since dendritic spine size correlates with synaptic properties, with small spines considered more plastic and large/medium spines more stable, these regional patterns suggest that sensory areas (V1) primarily suffer plasticity-related deficits, while association areas (PPC, DLPFC) experience loss in synaptic stability. This pattern mirrors the cognitive deficits in visual-spatial working memory seen in SZ.

Expert Commentary

The findings from Fish et al. add a nuanced understanding of synaptic pathology in schizophrenia, highlighting spatial specificity across the cortical hierarchy and the role of spine size in synaptic vulnerability. This suggests that SZ is not a uniform synaptic pathology but involves differential disruptions that may explain heterogeneous clinical manifestations.

The decreased spinophilin across all regions suggests a shared molecular substrate for synaptic loss, whereas the variable phalloidin changes hint at divergent cytoskeletal responses. The study’s focus on well-matched postmortem samples and advanced imaging techniques adds robustness, though limitations inherent to postmortem analyses, such as possible medication effects and variable agonal states, remain.

Future research integrating these findings with in vivo imaging, electrophysiology, and functional assessments could clarify mechanistic pathways toward developing targeted synaptoprotective interventions.

Conclusion

This comprehensive cortical study elucidates regionally and size-specific dendritic spine deficits in layer 3 pyramidal neurons of individuals with schizophrenia. The differential impact on small versus large spines across visual and association cortices supports a model in which SZ-mediated synaptic pathology disrupts cortical circuits involved in visual-spatial working memory by distinct mechanisms—impaired plasticity in sensory regions and synaptic destabilization in higher-order association areas. These insights provide critical directions for future mechanistic studies and potential therapeutic targets aimed at restoring synaptic integrity and cognitive function in schizophrenia.

Funding and ClinicalTrial.gov

The study was conducted with support from the Allegheny County Office of the Medical Examiner and affiliated academic institutions. No clinical trial registration applies as this is a neuropathological case-control study.

References

Fish KN, Sweet RA, MacDonald ML, Lewis DA. Regional Specificity of Cortical Layer 3 Dendritic Spine Deficits in Schizophrenia. JAMA Psychiatry. 2025 Sep 17:e252221. doi:10.1001/jamapsychiatry.2025.2221. PubMed PMID: 40960807; PMCID: PMC12444653.

Additional relevant literature:
– Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90-107.
– Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000 Jan;57(1):65-73.
– Penzes P, Cahill ME, Jones KA, et al. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011 Mar;14(3):285-293.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Relapse Trajectories and Antipsychotic Discontinuation in Schizophrenia: Insights from a Meta-Analysis and Contemporary EvidenceThis review synthesizes a meta-analysis of relapse trajectories following paliperidone discontinuation with evidence on antipsychotic maintenance and discontinuation strategies, highlighting individualized risk stratification and clinical iAug 27, 2026Time-Dependent Symptom Improvement in Schizophrenia: Insights from Six Antipsychotic TrialsThis analysis of six antipsychotic trials reveals distinct temporal patterns in the improvement of schizophrenia symptom domains, with hostility and excitement responding fastest and negative and cognitive symptoms improving more slowly, guAug 5, 2026Pluralistic Model Proposed for Schizophrenia Spectrum: Beyond DopamineA new narrative review synthesizing evidence from 1980 to 2025 argues that schizophrenia spectrum disorders cannot be explained solely by dopaminergic dysfunction. The authors propose a pluralistic model involving multiple neurochemical and cellular processes, with implications for treatment development and biomarker-based stratification.Jul 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
LB-102 in Acute Schizophrenia: A Promising Benzamide Antipsychotic with Demonstrated Efficacy and Safety
The phase 2 NOVA1 trial demonstrates that LB-102 significantly improves acute schizophrenia symptoms with a favorable safety profile, supporting its potential as a novel treatment option.
Jul 17, 2026
Serial Dependence in Working Memory Distinguishes Schizophrenia From Bipolar Disorder With PsychosisA multisite case-control study found repulsive serial bias in schizophrenia, attractive bias in healthy controls, and mixed patterns in bipolar disorder, supporting serial dependence as a potential cognitive biomarker across the psychosis sJun 9, 2026
When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t GuaranteedA large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.May 29, 2026